Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paweł Maciejewski is active.

Publication


Featured researches published by Paweł Maciejewski.


Atherosclerosis | 2010

Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the POLISH STEMI registry

Giuseppe De Luca; Lukasz A. Malek; Paweł Maciejewski; Wojciech Wąsek; Maciej Niewada; Bogumił Kamiński; Janusz Drze wiecki; Maciej Kośmider; Jacek Kubica; Witold Rużyłło; Jan Z. Peruga; Dariusz Dudek; Grzegorz Opolski; Sławomir Dobrzycki; Robert J. Gil; Adam Witkowski

BACKGROUND It has been shown that, among patients with ST-segment elevation myocardial infarction (STEMI), diabetes is associated with a significantly higher mortality. The aim of this study was to investigate in a large cohort of patients the impact of diabetes on mortality in a large cohort of patients with STEMI treated with primary angioplasty. METHODS Our population is represented by consecutive patients with STEMI treated by primary angioplasty and enrolled in the POLISH registry in 2003. All clinical, angiographic, and follow-up data were prospectively collected. Diagnosis of diabetes was based on history of diabetes at admission. RESULTS Among 7193 patients, 877 (12.2%) had diabetes at admission. Diabetes was associated with more advanced age (p<0.0001), higher prevalence of female gender (p<0.0001), hyperlipidemia (p<0.0001), shock at presentation (p<0.0001), renal failure (p<0.0001), previous myocardial infarction (p<0.0001), more often treated after 6h from symptom onset (p<0.0001). Diabetes was associated with more extensive coronary artery disease (p<0.0001), less often treated with stenting (p<0.0001). Diabetes was significantly associated with impaired epicardial reperfusion (TIMI 0-2: OR [95% CI]=1.81 [1.5-2.18], p<0.0001), that persisted after correction for baseline confounding factors (OR [95% CI]=1.33 [1.075-1.64], p=0.009). At a mean follow-up of 524+/-194 days, diabetes was associated with higher mortality (unadjusted cumulative mortality: 23.5% vs. 12.6%, unadjusted HR=1.95 [1.66-2.3], p<0.0001), that persisted after correction for confounding factors (adjusted cumulative mortality: 13.3% vs. 10.7%, adjusted HR=1.23 [1.04-1.46], p=0.013). CONCLUSIONS This study shows that among STEMI treated by primary angioplasty diabetes is independently associated with impaired epicardial reperfusion and higher mortality.


The Cardiology | 2009

Effects of vitamins C and E on the outcome after acute myocardial infarction in diabetics: a retrospective, hypothesis-generating analysis from the MIVIT study.

Tomasz Jaxa-Chamiec; Bronisław Bednarz; Krystyna Herbaczyńska-Cedro; Paweł Maciejewski; Leszek Ceremużyński

Background: There is significant evidence that reactive oxygen species play an important role in endothelial dysfunction, ischemia/reperfusion injury as well as in the pathogenesis of diabetes mellitus (DM). It is also known that vitamins C and E have substantial antioxidant properties. However, clinical evidence concerning this topic is insufficient so far. The aim of the present study was to determine if the administration of vitamins C and E influences the outcome in diabetic patients with acute myocardial infarction (AMI). Methods: Among 800 patients with AMI included in the MIVIT (Myocardial Infarction and Vitamins) study, 122 patients (15%) had confirmed DM. A retrospective analysis of the influence of vitamins C and E on 30-day cardiac mortality in patients with or without DM was performed. Results: There was a significant reduction in 30-day cardiac mortality in diabetic patients treated with antioxidant vitamins C and E [5 (8%) vs. 14 (22%); OR 0.32, 95% CI 0.11–0.93; p = 0.036]. Such an effect has not been observed in patients without DM [19 (6%) vs. 19 (6%); OR 0.97, 95% CI 0.51–1.85; p = 0.94]. Conclusion: The results suggest that early administration of antioxidant vitamins C and E in patients with AMI and concomitant DM reduces cardiac mortality.


European Heart Journal | 2009

Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality

Adam Witkowski; Paweł Maciejewski; Wojciech Wąsek; Łukasz A. Małek; Maciej Niewada; Bogumił Kamiński; Janusz Drzewiecki; Maciej Kośmider; Jacek Kubica; Witold Rużyłło; Jan Z. Peruga; Dariusz Dudek; Grzegorz Opolski; Sławomir Dobrzycki; R.J. Gil

AIMS The aim of this analysis was to examine the influence of different in-cath-lab antiplatelet regimens for the primary percutaneous coronary intervention (PCI) on all-cause mortality. METHODS AND RESULTS The study group consisted of 7193 patients (pts) undergoing primary PCI in 38 centres in 2003 in Poland. All patients received pretreatment with 300 mg of aspirin, 992 pts (14%) received glycoprotein (GP) IIb/IIIa inhibitors, 2690 pts (37%) were treated with 300 mg loading dose of clopidogrel, and 1566 (22%) received combined antiplatelet treatment with both GP IIb/IIIa inhibitors and clopidogrel. Remaining 1945 patients (27%) did not receive GP IIb/IIIa inhibitors or clopidogrel. Primary endpoint of the study was all-cause mortality up to 1 year from ST-segment elevation myocardial infarction (STEMI). One year mortality rates in the four groups were: 10.4%, 9.0%, 9.7%, and 15.3%, respectively. Propensity-adjusted survival analysis showed significant reduction of mortality for combination therapy with GP IIb/IIIa inhibitors and clopidogrel, clopidogrel alone, and GP IIb/IIIa inhibitors alone over aspirin alone. No additive effect on survival was seen for a combination therapy with GP IIb/IIIa inhibitors and clopidogrel in comparison to treatment with clopidogrel alone. CONCLUSION In this large cohort, multicentre STEMI registry in-cath-lab use of GP IIb/IIIa inhibitors and clopidogrel alone or in combination was associated with the reduction of 1 year all-cause mortality in the setting of primary PCI in comparison with aspirin only. However, the use of GP IIb/IIIa inhibitors on top of 300 mg loading dose of clopidogrel did not further reduce mortality.


American Journal of Cardiology | 2012

Right Ventricular Dysfunction and Exercise Capacity After Inferior (Posterior) Wall Acute Myocardial Infarction

Krzysztof Smarz; Beata Zaborska; Tomasz Jaxa-Chamiec; Paweł Maciejewski; Andrzej Budaj

Tissue Doppler echocardiography is a novel technique that can be used to diagnose right ventricular (RV) systolic dysfunction. Until recently, there have been no data on the influence of tissue Doppler-derived RV systolic dysfunction on exercise capacity after inferior (posterior) myocardial infarction (MI). We studied 90 consecutive patients (76% men, mean age 61 ± 10 years) with first inferior ST-segment elevation MI and left ventricular ejection fraction ≥45%. RV systolic dysfunction was defined as RV systolic myocardial velocity <11.5 cm/s at the basal segment of the RV free wall assessed by pulse tissue Doppler. Patients were categorized as with or without RV systolic dysfunction (RV systolic myocardial velocity 9.34 ± 1.36 and 13.74 ± 1.58 cm/s, respectively). A cardiopulmonary exercise test was performed before or soon after discharge (day 14 ± 10). Patients with RV systolic dysfunction had lower oxygen consumption assessed as percent predicted oxygen uptake in liters per minute and milliliters per kilogram per minute at their anaerobic threshold (61 ± 11% vs 69 ± 17%, p = 0.007; 53 ± 12% vs 61 ± 19%, p = 0.012, respectively) and at peak exercise (71 ± 12% vs 83 ± 16%, p = 0.0001; 62 ± 14% vs 74 ± 21%, p = 0.002, respectively). Multivariate regression analysis revealed that the following independent factors negatively influenced exercise capacity: RV systolic dysfunction, female gender, age, lower body mass index, current smoking, and maximal troponin I concentration. In conclusion, we found decreased exercise capacity in patients with systolic RV dysfunction assessed by pulse tissue Doppler in patients with inferior (posterior) wall acute MI despite preserved left ventricular function.


Kardiologia Polska | 2013

Assessment of the prognostic value of coronary angiography in patients with non-ST segment elevation myocardial infarction.

Paweł Maciejewski; Paweł Lewandowski; Wojciech Wąsek; Andrzej Budaj

BACKGROUND Management of patients with acute non-ST segment elevation myocardial infarction (NSTEMI) depends on risk evaluation. The recommended approach involves the use of risk stratification tools such as TIMI and GRACE risk scores. However, these clinical scores do not include variables derived from coronary angiography which is currently performed in most patients. AIM To evaluate the prognostic value of adding selected coronary angiographic parameters to the established TIMI and GRACE risk scores. METHODS We studied consecutive patients with NSTEMI who underwent coronary angiography. We evaluated selected vascular variables (vessel score, lesion location, percent stenosis, presence of thrombus, lesion length, vessel size, TIMI flow, lesion type according to the ACA/AHA classification, and extent score) and estimated risk using the TIMI and GRACE scores. We assessed total mortality at 30 days, 180 days, and 3 years. To determine the prognostic value of vascular variables and risk scores, we used a logit model and the Hosmer-Lemeshow test. Diagnostic utility of the models was measured by the area under receiver operating characteristic (ROC) curves. To determine usefulness of selected vascular variables as outcome predictors in addition to the GRACE and TIMI scores, we used Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) indices. RESULTS The study included 237 patients (mean age 65.5 years, 62% men). The TIMI and GRACE risk scores were good predictors of mortality in the evaluated periods. Among vascular variables, independent prognostic factors included the extent score which predicted mortality at 30 days (odds ratio [OR] 12.7, 95% confidence interval [CI] 1.6-99, p = 0.016), 180 days (OR 8.8, 95% CI 2.3-33.7, p = 0.002), and 3 years (OR 3.5, 95% CI 1.6-8.0, p = 0.003), and distal lesion location which predicted mortality at 180 days (OR 3.1, 95% CI 1.0-9.4). Addition of the extent score to the TIMI risk score improved the prognostic value of the latter at all time points, as confirmed by NRI and IDI indices. The GRACE risk score itself had good prognostic value which was not significantly improved by any of the evaluated vascular variables. CONCLUSIONS The extent score added to the TIMI risk score improves the prognostic value of the latter in patients with NSTEMI. Angiographic variables should be more widely used in risk stratification models in patients with acute coronary syndromes.


Kardiologia Polska | 2013

Can we improve the accuracy of risk assessment in patients with non ST-segment elevation acute coronary syndromes?

Wojciech Wąsek; Paweł Maciejewski; Anna Toruń; Maciej Niewada; Bogumił Kamiński; Beata Kłosiewicz-Wąsek; Bronisław Bednarz; Andrzej Budaj

BACKGROUND In patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS), the long-term risk of deathand myocardial infarction (MI) is estimated by scores based on noninvasively derived variables. Much less is known about the relation between the degree of atherosclerotic burden in the coronary tree and the long-term risk of patients with NSTE-ACS. AIM To evaluate the accuracy of a wide spectrum of coronary angiographic and clinical data in predicting outcomes ina long-term follow-up of patients successfully treated invasively for NSTE-ACS. METHODS The study group consisted of 112 consecutive patients (age 62 ± 10 years; 76 men) treated invasively for NSTE-ACS.27 (24%) patients had a history of diabetes mellitus (DM) and 37 (33%) patients a history of MI. The coronary angiograms priorto intervention were evaluated blindly for the four angiographic scores: (1) Stenosis score derived from the assessment of thedegree of stenosis in 15 segments of the coronary tree; (2) Vessel score showing the number of main vessels stenosed > 70%; (3) Extensity score assessing the proportion of lumen length irregularity in 15 segments; and (4) Complexity score describingthe number of complex plaques. The angiographic analysis also focused on the flow, presence of thrombus and collateralsupply prior to intervention (according to TIMI) and the size of the culprit lesion vessel. The intervention was successful in 95% of cases. All patients were followed-up for 6-24 months for the occurrence of death or MI. RESULTS In the follow-up period, the composite end point of death or MI occurred in 20 (17%) patients. In order to indicate therisk predictors from the group of clinical and angiographic variables (age, sex, history of DM, history of MI, four angiographicscores and culprit lesion vessel characterisation), logistic regression analysis was performed. The independent angiographic predictors of composite end point (selected by forward conditional selection) were stenosis score (OR 1.13; 95% CI 1.05-1.2;p < 0.001) and size of the vessel (OR 0.08; 95% CI 0.01-0.6; p = 0.02). CONCLUSIONS Our preliminary data shows that attempting to add angiographic variables into the risk assessment scoring systems in order to strengthen their predictive accuracy is justified.


Vasa-european Journal of Vascular Medicine | 2018

A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection

Paweł Lewandowski; Jakub Baran; Paweł Maciejewski; Andrzej Budaj

BACKGROUND Iatrogenic pseudoaneurysms (IPA) are treated with ultrasound-guided thrombin injections (UGTI). We describe a novel technique for IPA repair that applies UGTI with thrombin foam (UGTFI). METHODS AND RESULTS Successful obliteration of 6 IPAs (IPA without a neck, n = 5; with a neck, n = 1) in 6 patients (2 males, aged 68 ± 1 years, 4 females, aged 59 ± 11 years) was performed by using UGTFI. The dose of administered thrombin was 25-75 IU. No microembolization phenomenon and no serious clinical complications were observed. CONCLUSIONS Treatment of IPA with UGTFI may reduce the embolization rate, risk of IPA cavity thrombin leakage, required drug dose. Use of the thrombin foam could be the next step in the development of the UGTI, particularly in the treatment of IPA without a neck.


Kardiologia Polska | 2005

Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of the multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial.

Bronisław Bednarz; Tomasz Jaxa-Chamiec; Paweł Maciejewski; Michał Szpajer; Krzysztof Janik; Jacek Gniot; Teresa Kawka-Urbanek; Dorota Drozdowska; Jacek Gessek; Henryk Laskowski


Kardiologia Polska | 2005

Antioxidant effects of combined vitamins C and E in acute myocardial infarction. The randomized, double-blind, placebo controlled, multicenter pilot Myocardial Infarction and VITamins (MIVIT) trial.

Tomasz Jaxa-Chamiec; Bronisław Bednarz; Dorota Drozdowska; Jacek Gessek; Jacek Gniot; Krzysztof Janik; Teresa Kawka-Urbanek; Paweł Maciejewski; Michał Ogórek; Michał Szpajer


Kardiologia Polska | 2011

Efficacy and safety of closing postcatheterisation pseudoaneurysms with ultrasound-guided thrombin injections using two approaches: bolus versus slow injection. A prospective randomised trial.

Paweł Lewandowski; Paweł Maciejewski; Wojciech Wąsek; Tomasz Pasierski; Andrzej Budaj

Collaboration


Dive into the Paweł Maciejewski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dariusz Dudek

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Maciej Lesiak

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Adam Witkowski

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Andrzej Ochała

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar

Jacek Legutko

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maciej Karcz

Medical University of Łódź

View shared research outputs
Top Co-Authors

Avatar

Maciej Niewada

Medical University of Warsaw

View shared research outputs
Researchain Logo
Decentralizing Knowledge